Nektr Technologies Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Liquidation
Nektr Technologies General Information
Description
Developer of a synthetic compound designed for the treatment of several infectious diseases. The company has developed a patented synthetic antimicrobial topical pharmaceutical gel that has potent antibacterial and antifungal activity against all tested pathogens, regardless of their resistance profile which has been validated by a number of world-leading research institutes and the technology achieved through the sustained release of reactive oxygen species (ROS), enabling clients to get an area of anti-microbial resistance, nasal decontamination and medical device coatings.
Contact Information
Website
www.nektr.ieCorporate Office
- Finisklin Business and Technology Park
- Sligo F91 HF66
- Sligo
- Ireland
Corporate Office
- Finisklin Business and Technology Park
- Sligo F91 HF66
- Sligo
- Ireland
Nektr Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Bankruptcy: Liquidation | 20-Dec-2023 | Completed | Bankruptcy: Liquidation | |||
| 6. Later Stage VC | Cancelled | Clinical Trials - Phase 3 | ||||
| 5. Later Stage VC | 06-May-2021 | Completed | Clinical Trials - Phase 3 | |||
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 3. Early Stage VC | 17-Apr-2019 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 23-Mar-2018 | $493K | $493K | Completed | Startup | |
| 1. University Spin-Out | 01-Dec-2017 | Completed | Startup |
Nektr Technologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
Nektr Technologies Comparisons
Industry
Financing
Details
Nektr Technologies Competitors (3)
One of Nektr Technologies’s 3 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Bausch Health Companies | Corporation | Laval, Canada |
Nektr Technologies Signals
Nektr Technologies FAQs
-
When was Nektr Technologies founded?
Nektr Technologies was founded in 2016.
-
Where is Nektr Technologies headquartered?
Nektr Technologies is headquartered in Sligo, Ireland.
-
What is the size of Nektr Technologies?
Nektr Technologies has 6 total employees.
-
What industry is Nektr Technologies in?
Nektr Technologies’s primary industry is Drug Discovery.
-
Is Nektr Technologies a private or public company?
Nektr Technologies is a Private company.
-
What is Nektr Technologies’s current revenue?
The current revenue for Nektr Technologies is .
-
How much funding has Nektr Technologies raised over time?
Nektr Technologies has raised $2.79M.
-
Who are Nektr Technologies’s competitors?
Spero Therapeutics, Melinta Therapeutics, and Bausch Health Companies are competitors of Nektr Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process